Epcoritamb plus lenalidomide and rituximab improves PFS and complete response in patients with relapsed/refractory follicular lymphoma in second line compared with lenalidomide and rituximab alone.
A treatment strategy of targeted therapy first allowed more than half of patients with newly diagnosed DLBCL to achieve a CR without chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback